Recombinant Human CLEC9a Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CLEC9a Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by flow cytometry for its ability to bind a ligand expressed in FasL-treated mouse B cells. Sancho, D. et al. (2009) Nature 458:899. At 100 ng/mL, >50% of necrotic cells bind to Recombinant Human CLEC9a.
• Source: Mouse myeloma cell line, NS0-derived human CLEC9a protein
  

  Met-Asp	Human IgG1 (Pro100-Lys330)	IEGR	Human CLEC9a (Lys57-Val241) Accession # Q6UXN8
  N-terminus			C-terminus

• Accession #: Q6UXN8
• N-terminal Sequence: Met
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CLEC9A
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47.8 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-65 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CLEC9a Fc Chimera Protein, CF

• CD370
• CLEC9a
• C-type lectin domain family 9 member A
• C-type lectin domain family 9, member A
• DNGR1
• HEEE9341
• UNQ9341

Background

CLEC9A (C-type lectin domain family 9 member A), also known as DNGR-1, is a type II transmembrane glycoprotein member of the C-type lectin superfamily (1). Mature mouse CLEC9A consists of a 35 amino acid (aa) cytoplasmic domain with an ITAM-like motif, a 21 aa transmembrane segment, and a 185 extracellular domain (ECD) that contains a stalk region and one C-type lectin domain (CTLD) (2-4). Within the ECD, human CLEC9A shares 57% aa sequence identity with mouse and rat CLEC9A. Although the CTLD of CLEC9A structurally resembles that of other C-type lectins, it lacks the conserved residues that typically mediate calcium and carbohydrate binding. CLEC9A is expressed as a disulfide-linked homodimer of approximately 50 kDa N-glycosylated subunits (2, 4). Human CLEC9A expression is restricted to a subpopulation of BDCA-3⁺ conventional dendritic cells (cDC) and CD16^- monocytes (2-5). BDCA-3⁺ cDC are analagous to mouse CD8⁺ cDC which are specialized in antigenic cross-presentation in complex with MHC class I molecules (6). In mouse, CLEC9A is additionally expressed on plasmacytoid dendritic cells (3, 4). CLEC9A ligation enhances antigen uptake and processing, leading to presentation on MHC class I and cytotoxic T cell (CTL) priming (2-5, 7). Its recognition of filamentous actin in dead cells is important for triggering an immune response to necrotic cell debris (8-10). CLEC9A is also required for the presentation of viral proteins and the subsequent CTL-mediated killing of virus-infected cells (11, 12). CLEC9A signaling triggers activation of the tyrosine kinase Syk (2, 8).

1. Kerrigan, A.M. and G.D. Brown (2010) Immunol. Rev. 234:335.
2. Huysamen, C. et al. (2008) J. Biol. Chem. 283:16693.
3. Caminschi, I. et al. (2008) Blood 112:3264.
4. Sancho, D. et al. (2008) J. Clin. Invest. 118:2098.
5. Schreibelt, G. et al. (2012) Blood 119:2284.
6. Dudziak, D. et al. (2007) Science 315:107.
7. Poulin, L.F. et al. (2010) J. Exp. Med. 207:1261.
8. Sancho, D. et al. (2009) Nature 458:899.
9. Ahrens, S. et al. (2012) Immunity 36:635.
10. Zhang, J.-G. et al. (2012) Immunity 36:646.
11. Iborra, S. et al. (2012) J. Clin. Invest. 122:1628.
12. Zelenay, S. et al. (2012) J. Clin. Invest. 122:1615.

Publications for CLEC9a (6049-CL)(3)

Publications using 6049-CL

• LL Eggink, KF Roby, R Cote, J Kenneth Ho An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides J Immunother Cancer, 2018-04-17;6(1):28. 2018-04-17 [PMID: 29665849] (Binding Assay, Human)
• T Uto, T Fukaya, H Takagi, K Arimura, T Nakamura, N Kojima, B Malissen, K Sato Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity Nat Commun, 2016-04-12;7(0):11273. 2016-04-12 [PMID: 27068492] (Enzyme Assay, Human)
• Iborra S, Izquierdo HM, Martinez-Lopez M, Blanco-Menendez N, Reis E Sousa C, Sancho D The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J. Clin. Invest., 2012-04-16;122(5):1628-43. 2012-04-16 [PMID: 22505455] (Flow Cytometry, Mouse)

Review for CLEC9a (6049-CL) (1)

Average Rating: 5

(Based on 1 review)

reviewed by: Verified Customer ELISA 03/30/2025

Summary

• Application: ELISA
• Lot: TIT0424021

Bioinformatics

• Gene Symbol: CLEC9A
• Uniprot:
  • Q6UXN8()